Spero Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRO research report →
Price Chart
About the company
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients.
- CEO
- Esther Rajavelu
- IPO
- 2017
- Employees
- 25
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on SPRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $43.23M
- P/E
- -1.69
- PEG
- 0.00
- P/S
- 1.21
- P/B
- 61.61
- EV/EBITDA
- -7.17
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 17.61%
- Net Margin
- -73.94%
- ROE
- -75.22%
- ROIC
- 12.86%
Latest fiscal year · YoY change
- Revenue
- $59.62M+24.3%
- Gross Profit
- $59.62M+222.2%
- Op Income
- $-24,000
- Net Income
- $8.57M+112.5%
- EPS
- $0.15+111.8%
- OCF Growth
- +46.2%
- FCF Growth
- +46.2%
- 52W High
- $3.08
- 52W Low
- $0.73
- 50D MA
- $1.11
- 200D MA
- $1.89
- Beta
- 1.56
- RSI (14)
- 23
- Avg Volume
- 529.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Spero reported no Q2 revenue, but highlighted a major strategic reset into immunology after Utebzi’s FDA approval, backed by a $105 million royalty financing and cash runway into the second half of 2029.· August 12, 2026
- Utebzi received FDA approval; GSK expects U.S. availability in the second half of this year.
- Spero in-licensed SP001 from Innovent, gaining worldwide rights outside Greater China and shifting the pipeline toward immune-mediated diseases.
- The company closed $105 million of nonrecourse royalty financing tied to future Utebzi payments, strengthening the balance sheet without exposing other assets.
- Management plans to move SP001 into Phase II in IgG4-RD in the second quarter of 2027, with up to 15 patients per arm in an open-label, two-arm study.
- Cash and cash equivalents were $50.8 million at June 30, and management said runway now extends into the second half of 2029.
For Q2 2026, Spero reported no revenue versus $14.2 million in Q2 2025. R&D expense was $3.4 million, down from $10.7 million year over year, while G&A expense rose to $6.5 million from $5.9 million. Net loss was $9.6 million, or $0.16 per diluted share, versus a net loss of $1.7 million, or $0.03 per diluted share, in the prior-year quarter. Cash and cash equivalents were $50.8 million at June 30, before July proceeds from the $105 million royalty financing. Management said that cash plus the financing proceeds should fund the $35 million nonrefundable upfront payment to Innovent and operating expenses/capital expenditures into the second half of 2029.
Esther Rajavelu framed the quarter as a turning point: after Utebzi’s approval, Spero is repositioning as an immunology company centered on SP001. She emphasized four major milestones in the last 90 days: the FDA approval, the SP001 in-license, the $105 million financing, and the hiring of a CMO. Her tone was upbeat and strategic, stressing that the financing unlocks immediate value from Utebzi while funding the next stage of development.
No separate CFO spoke; Esther Rajavelu delivered the financial review. She said cash and cash equivalents were $50.8 million at June 30, and that the July royalty financing, combined with existing cash, should cover the $35 million upfront payment to Innovent plus operating expenses and capital expenditures into the second half of 2029. She also outlined the financing terms: $105 million of senior secured notes, 10% annual interest, 9-year maturity, paid solely from GSK milestone and royalty receipts, with Spero retaining 35% of additional GSK milestone and royalty proceeds after repayment. Quarterly results reflected no revenue, lower R&D spend due to the earlier completion of the Utebzi Phase III trial, and higher G&A from business development, legal and consulting costs.
Analysts focused on how SP001 would be positioned in IgG4-RD, how success would be measured, and whether it could complement or compete with B-cell depleters such as Uplizna. Debra Zack said the Phase II study is intended to establish proof of concept, looking at symptom control, disease control over time, and reductions in steroids and DMARD use; she said flare suppression would be more of a Phase III endpoint. On positioning, management said SP001 could potentially be used after or alongside existing therapies because it targets upstream T-cell/B-cell signaling rather than B cells alone. Esther added that IgG4-RD is still an early and evolving market, and that diagnosis rates could rise as the disease becomes better recognized and the new diagnostic code improves awareness.
The call gave Spero a clearer post-Utebzi strategy, with a new lead asset in SP001 and a focused move into immune-mediated disease. Management also pointed to a long cash runway into the second half of 2029, reducing near-term financing pressure. The SP001 program is already clinically de-risked to some extent by prior Phase I and Phase Ib data, and management believes its upstream mechanism could differentiate it in IgG4-RD.
Q2 was financially weak on a reported basis, with no revenue, a $9.6 million net loss, and lower R&D activity after Utebzi’s Phase III work ended. SP001 is still early, with Phase II not expected until the second quarter of 2027, so the new strategy has a long timeline before any meaningful clinical readout. Management also acknowledged uncertainty around market uptake, saying they could not comment on Uplizna’s commercial performance and that IgG4-RD remains an early, evolving disease area.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.9%
- Shares Outstanding
- 58.26M
- Float Shares
- 47.14M
of shares held by institutions
66 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gsk PLC | 9.19M | 0 |
| Pfizer Inc | 2.36M | 0 |
| Vanguard Group Inc | 2.08M | ▲ 93.61K |
| Vanguard Capital Management LLC | 2.04M | 0 |
| Mackenzie Financial Corp | 1.83M | ▲ 1.83M |
| Renaissance Technologies LLC | 1.41M | ▲ 461.88K |
| Affinity Asset Advisors, LLC | 1.30M | ▲ 1.30M |
| Arrowstreet Capital, Limited Partnership | 997.12K | ▲ 664.15K |
| Verdad Advisers, LP | 805.70K | ▲ 754.37K |
| Raymond James Financial Inc | 755.63K | ▲ 233.93K |
| Citadel Advisors LLC | 725.99K | ▲ 725.99K |
| Blackrock, Inc. | 594.26K | ▼ 146 |
Held by 31 ETFs
Biggest fund positions in SPRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Rajavelu Esther | sell | 40,851 |
| Nov 10, 26 | HO WILLIAM | other | 100,000 |
| Nov 10, 26 | HO WILLIAM | other | 0 |
| Aug 3, 26 | Zack Debra | other | 324,675 |
| Aug 3, 26 | Zack Debra | other | 162,311 |
| Aug 3, 26 | Zack Debra | other | 0 |
| Jun 23, 26 | Deshpande Milind | other | 10,000 |
| Jun 23, 26 | Deshpande Milind | other | 20,000 |
| Jun 23, 26 | Tregoning Kathleen | other | 10,000 |
| Jun 23, 26 | Tregoning Kathleen | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPRO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SPRO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
globenewswire.com · Nov 12
Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
globenewswire.com · Nov 10
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 4
Spero Therapeutics to Present at Investor Conferences in November
globenewswire.com · Nov 2
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
benzinga.com · Oct 28
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
globenewswire.com · Oct 26
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
marketbeat.com · Oct 21
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
globenewswire.com · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
